Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REWENEC 01: FOLFIRI + Zimberelimab + Domvanalimab in Second-Line Neuroendocrine Carcinoma
NCT07337447Phase 2Not yet recruiting
- Sponsor
- Hospices Civils de Lyon
- Start
- Apr 2026
- Primary completion
- Apr 2029
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of zimberelimab, domvanalimab in neuroendocrine carcinoma (NEC), sponsored by Hospices Civils de Lyon. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
zimberelimabdomvanalimab
03
Conditions
neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on NCT07337447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07337447.